Literature DB >> 10219883

Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.

A Sartorio1, M Arosio, A Conti, S Ferrero, S Porretti, G Faglia.   

Abstract

Serum aminoterminal propeptide of type III procollagen (PIIINP) levels, a reliable marker of collagen formation, were evaluated in children (C=7) and adults with childhood-onset (CO=10) and acquired (A=18) GH deficiency (GHD) before, during and after withdrawal of rec-GH therapy (C=0.6 IU/kg/week, CO=0.5 IU/kg/week, A=0.25 IU/kg/week). The duration of treatment was 12 months for C and A and 6 months for CO; investigations were carried out before and at 3, 6, 9 and 12 months (for C and A) and at 3 and 6 months (for CO) of GH treatment and 6 months after the withdrawal of therapy (for A and CO). Data obtained from patients were compared with those recorded in two age- and sex-matched control groups. Before treatment, serum PIIINP levels were significantly lower (p<0.001) in C with GHD (mean+/-SE: 2.9+/-0.4 ng/ml) than in controls (6.1+/-0.4 ng/ml), while no significant differences were recorded between adults with CO/A-GHD (3.7+/-0.5 ng/ml and 3.4+/-0.2 ng/ml) and controls (3.2+/-0.2 ng/ml). GH treatment caused a significant increase (p<0.0001) of PIIINP levels both in C (3rd month: 4.4+/-0.2 ng/ml, 6th month: 5.1+/-0.4 ng/ml, 12th month: 5.1+/-0.5 ng/ml), CO-GHD (3rd month: 12.7+/-1.2 ng/ml; 6th month: 10.2+/-0.6 ng/ml) and A-GHD (3rd month: 10.0+/-1.0 ng/ml; 6th month: 8.4+/-0.6 ng/ml; 12th month: 7.0+/-0.7 ng/ml), the increase being dose-dependent (more marked and sustained in adults with CO-GHD). The maximal stimulation of collagen synthesis occurred after 3 months of GH treatment in adults with GHD, while a more gradual and less relevant increase was observed in C with GHD. Six months after the withdrawal of GH therapy, serum PIIINP levels of adults with CO-GHD (3.6+/-0.3 ng/ml) were similar to those recorded before treatment, while in adults with A-GHD serum PIIINP levels (2.6+/-0.2 ng/ml) were significantly lower (p<0.01) than in basal condition. In conclusion, our study shows that: a) GHD is associated with a reduction of soft tissue formation in children, while it seems to exert no relevant effects in adults with GHD; b) GH therapy causes a rapid stimulation of collagen turnover, which shows a different pattern in children and adults; c) the GH-induced stimulation of collagen synthesis is rapidly removed after the withdrawal of GH treatment. For these reasons, the determination of peripheral markers of GH effects appears useful for the monitoring of GH therapy and can contribute to assess the "tailored" substitutive dose for the individual patient.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219883     DOI: 10.1007/BF03343537

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  The biosynthesis of collagen and its disorders (first of two parts).

Authors:  D J Prockop; K I Kivirikko; L Tuderman; N A Guzman
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

2.  Serum aminoterminal propeptide of type III procollagen: a potential predictor of the response to growth hormone therapy.

Authors:  P Tapanainen; L Risteli; M Knip; M L Käär; J Risteli
Journal:  J Clin Endocrinol Metab       Date:  1988-12       Impact factor: 5.958

3.  Comparative study of the changes in insulin-like growth factor-I, procollagen-III N-terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone.

Authors:  P Bergmann; J Valsamis; J Van Perborgh; J De Schepper; G Van Vliet
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

4.  Serum procollagen-III as indicator of therapeutic effect in children treated for somatotropin deficiency.

Authors:  G Lindstedt; L Weijkum; P A Lundberg; K Albertsson-Wikland
Journal:  Clin Chem       Date:  1984-11       Impact factor: 8.327

5.  Collagen formation and degradation increase during growth hormone therapy in children.

Authors:  E Vihervuori; M Turpeinen; M A Siimes; H Koistinen; R Sorva
Journal:  Bone       Date:  1997-02       Impact factor: 4.398

6.  New markers of bone and collagen turnover in children and adults with growth hormone deficiency.

Authors:  A Sartorio; A Conti; M Monzani
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

7.  Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders.

Authors:  P Trivedi; J Risteli; L Risteli; P C Hindmarsh; C G Brook; A P Mowat
Journal:  Pediatr Res       Date:  1991-09       Impact factor: 3.756

8.  Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.

Authors:  G Saggese; G I Baroncelli; S Bertelloni; L Cinquanta; G Di Nero
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

9.  Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome.

Authors:  A Piovesan; M Terzolo; G Reimondo; A Pia; A Codegone; G Osella; A Boccuzzi; P Paccotti; A Angeli
Journal:  Horm Metab Res       Date:  1994-05       Impact factor: 2.936

10.  Ultrastructural identification of extension aminopropeptides of type I and III collagens in human skin.

Authors:  R Fleischmajer; R Timpl; L Tuderman; L Raisher; M Wiestner; J S Perlish; P N Graves
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

View more
  2 in total

1.  Effects of surgery on peripheral N-terminal propeptide of type III procollagen in patients with Crohn's disease.

Authors:  Matilde De Simone; Michele M Ciulla; Ugo Cioffi; Luca Poggi; Barbara Oreggia; Roberta Paliotti; Fiorenzo Botti; Alberto Carrara; Fiorenza Agosti; Alessandro Sartorio; Ettore Contessini-Avesani
Journal:  J Gastrointest Surg       Date:  2007-08-09       Impact factor: 3.452

2.  Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.

Authors:  A Sartorio; G Conte; A Conti; A Masala; S Alagna; P Rovasio; G Faglia
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.